Jie Yu

Jie Yu

Auto-generated profile, based on publicly available information

Jie Yu

Oncology Drug Discovery Unit, Takeda Development Center Americas (TDCA), Inc., Lexington, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
KIKenichi Iwai
Kenichi Iwai
TNTadahiro Nambu
Tadahiro Nambu
RDRyo Dairiki
Ryo Dairiki
MOMomoko Ohori
Momoko Ohori
JYJie Yu
Jie Yu
AOAkihiro Ohashi
Akihiro Ohashi
Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell division cycle 7 (CDC7) has recently attracted attention as a target. We have developed an oral CDC7-selective inhibitor, TAK-931, as a candidate clinical anticancer drug. TAK-931 induced S phase delay and RS. TAK-931–induced RS caused mitotic aberrations through centrosome dysregulation and chromosome missegregation, resulting in irreversible antiproliferative effects in cancer cells. TAK-931 exhibited significant antiproliferative activity in preclinical animal models. Furthermore, in indication-seeking studies using large-scale cell panel data, TAK-931 exhibited higher antiproliferative activities in RAS-mutant versus RAS–wild-type cells; this finding was confirmed in pancreatic patient-derived xenografts. Comparison analysis of cell panel data also demonstrated a unique efficacy spectrum for TAK-931 compared with currently used chemotherapeutic drugs. Our findings help to elucidate the molecular mechanisms for TAK-931 and identify potential target indications.

21 May 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
KIKenichi Iwai
Kenichi Iwai
TNTadahiro Nambu
Tadahiro Nambu
YKYukie Kashima
Yukie Kashima
JYJie Yu
Jie Yu
KEKurt Eng
Kurt Eng
AOAkihiro Ohashi
Akihiro Ohashi
Potential combination partners of a CDC7 inhibitor TAK-931 were identified to guide its clinical development strategy.

18 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
TMTomoko Yamamori Morita
Tomoko Yamamori Morita
JYJie Yu
Jie Yu
YKYukie Kashima
Yukie Kashima
RKRyo Kamata
Ryo Kamata
GYGaku Yamamoto
Gaku Yamamoto
AOAkihiro Ohashi
Akihiro Ohashi
Serine/threonine kinase, cell division cycle 7 (CDC7) is critical for initiating DNA replication. TAK-931 is a specific CDC7 inhibitor, which is a next-generation replication stress (RS) inducer. This study preclinically investigates TAK-931 antitumor efficacy and immunity regulation. TAK-931 induce RS, generating senescence-like aneuploid cells, which highly expressed inflammatory cytokines and chemokines (senescence-associated secretory phenotype, SASP). In vivo multilayer-omics analyses in gene expression panel, immune panel, immunohistochemistry, RNA sequencing, and single-cell RNA sequencing reveal that the RS-mediated aneuploid cells generated by TAK-931 intensively activate inflammatory-related and senescence-associated pathways, resulting in accumulation of tumor-infiltrating immune cells and potent antitumor immunity and efficacy. Finally, the combination of TAK-931 and immune checkpoint inhibitors profoundly enhance antiproliferative activities. These findings suggest that TAK-931 has therapeutic antitumor properties and improved clinical benefits in combination with conventional immunotherapy.

1 January 2009 in Acta Physico-Chimica Sinica
Verified
Journal Article
Open access
PDF file
MSMa Shi-Tang
Ma Shi-Tang
LPLiu Pei-Xun
Liu Pei-Xun
LWLong Wei
Long Wei
YJYu Jie
Yu Jie
XYXu Yang
Xu Yang